Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Tax loss deal?

<< Previous

Bullboard Posts

Next >>

Comment by r0naldon Dec 29, 2020 8:13am

117 Views

Post# 32189950

RE:RE:Tax loss deal?

From Q3 2020 earnings call:

"Prasath Pandurangan

Hi, good morning. Thanks for taking my questions. Firstly, could you – is there any progress in terms of taking advantage of tax losses?

Craig Mull

Yes, we’ve made a significant progress. We are in serious discussions, including drafting of agreements with a partner that will co-promote our hospital products. And with that, we believe that we will be able to access the Cardiome losses as we are conducting an active business any area that Cardiome had participated in, and we expect to be able to utilize those losses as soon as the end of 2020."

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)